PDGFRβ expression in tumor stroma of pancreatic adenocarcinoma as a reliable prognostic marker

Medical Oncology

Volumn 29, Issue 4, 2012, Pages 2824-2830

  Yuzawa, Sayaka ^a   Kano, Mitsunobu R ^b   Einama, Takahiro ^c   Nishihara, Hiroshi ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Pancreatic adenocarcinoma; PDGFR ; Prognosis; SMA; Tumor stroma

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CD31 ANTIGEN; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CELL ACTIVATION; CLINICAL ARTICLE; FEMALE; FIBROBLAST; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; LYMPHATIC SYSTEM; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREATIC STELLATE CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STROMA CELL; SURVIVAL TIME;

ACTINS; ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SURVIVAL RATE;

EID: 84867979311     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0193-0     Document Type: Article

References (30)

1. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-13.
2. Katz MHG, Hwang R, Fleming JB, et al. Tumor-node-metastasis staging of pancreatic adenocarcinoma. CA Cancer J Clin. 2008;58:111-25.
3. Smith RA, Tang J, Tudur-Smith C, et al. Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer. Br J Cancer. 2011;104:1440-51.
4. Singh P, Srinivasan R, Wig JD. Major molecular markers in pancreatic ductal adenocarcinoma and their roles in screening, diagnosis, prognosis, and treatment. Pancreas. 2011;40:644-52.
5. Mitsunaga S, Hasebe T, Iwasaki M, et al. Important prognostic histological parameters for patients with invasive ductal carcinoma of the pancreas. Cancer Sci. 2005;96:858-65.
6. Farrow B, Albo D, Berger DH. The role of the tumor microenvironment in the progression of pancreatic cancer. J Surg Res. 2008;149:319-28.
7. Erkan M, Reiser-Erkan C, Michalski CW, et al. Tumor microenvironment and progression of pancreatic cancer. Exp Oncol. 2010;32:128-31.
8. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6:392-401.
9. Watsky MA, Weber KT, Sun Y, et al. New insights into the mechanism of fibroblast to myofibroblast transformation and associated pathologies. Int Rev Cell Mol Biol. 2010;282:165-92.
10. Tang WW, Ulich TR, Lacey DL, et al. Platelet-derived growth factor-BB induces renal tubulointerstitial myofibroblast formation and tubulointerstitial fibrosis. Am J Pathol. 1996;148:1169-80.
11. Kaur H, Chaurasia SS, de Medeiros FW, et al. Corneal stroma PDGF blockade and myofibroblast development. Exp Eye Res. 2009;88:960-5.
12. Paulsson J, Sjöblom T, Micke P, et al. Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol. 2009;175:334-41.
13. Betsholtz C. Insight into the physiological functions of PDGF through genetic studies in mice. Cytokine Growth Factor Rev. 2004;15:215-28.
14. Ostman A, Heldin C-H. PDGF receptors as targets in tumor treatment. Adv Cancer Res. 2007;97:247-74.
15. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002;347:481-7.
16. Japan Panceas Society. Classification of pancreatic carcinoma. 3rd ed. Tokyo: Kanehara Co.; 2011.
17. Edge SB. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2009.
18. Omary MB, Lugea A, Lowe AW, et al. The pancreatic stellate cell: a star on the rise in pancreatic diseases. J Clin Invest. 2007;117:50-9.
19. Erkan M, Michalski CW, Rieder S, et al. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol. 2008;6:1155-61.
20. Apte MV, Haber PS, Applegate TL, et al. Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture. Gut. 1998;43:128-33.
21. Masamune A, Watanabe T, Kikuta K, et al. Roles of pancreatic stellate cells in pancreatic inflammation and fibrosis. Clin Gastroenterol Hepatol. 2009;7:S48-54.
22. Apte MV, Park S, Phillips PA, et al. Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas. 2004;29:179-87.
23. Bachem MG, Schünemann M, Ramadani M, et al. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology. 2005;128:907-21.
24. Hwang RF, Moore T, Arumugam T, et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res. 2008;68:918-26.
25. Vonlaufen A, Joshi S, Qu C, et al. Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res. 2008;68:2085-93.
26. Hägglöf C, Hammarsten P, Josefsson A, et al. Stromal PDGFRbeta expression in prostate tumors and non-malignant prostate tissue predicts prostate cancer survival. PLoS ONE. 2010;5:e10747.
27. Forsberg K, Valyi-Nagy I, Heldin CH, et al. Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Proc Natl Acad Sci USA. 1993;90:393-7.
28. Shao ZM, Nguyen M, Barsky SH. Human breast carcinoma desmoplasia is PDGF initiated. Oncogene. 2000;19:4337-45.
29. Zeisberg M, Strutz F, Müller GA. Role of fibroblast activation in inducing interstitial fibrosis. J Nephrol. 2000;13:S111-20.
30. Bronzert DA, Pantazis P, Antoniades HN, et al. Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. Proc Natl Acad Sci USA. 1987;84:5763-7.